CA2806647C - 5-ht2b receptor antagonists - Google Patents

5-ht2b receptor antagonists Download PDF

Info

Publication number
CA2806647C
CA2806647C CA2806647A CA2806647A CA2806647C CA 2806647 C CA2806647 C CA 2806647C CA 2806647 A CA2806647 A CA 2806647A CA 2806647 A CA2806647 A CA 2806647A CA 2806647 C CA2806647 C CA 2806647C
Authority
CA
Canada
Prior art keywords
compound
acid
mmol
cdc13
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2806647A
Other languages
English (en)
French (fr)
Other versions
CA2806647A1 (en
Inventor
Johannes Wilhelmus John F. Thuring
Luc August Laurentius Ver Donck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2806647A1 publication Critical patent/CA2806647A1/en
Application granted granted Critical
Publication of CA2806647C publication Critical patent/CA2806647C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2806647A 2010-09-01 2011-08-30 5-ht2b receptor antagonists Active CA2806647C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10174880 2010-09-01
EP10174880.4 2010-09-01
PCT/EP2011/064906 WO2012028614A1 (en) 2010-09-01 2011-08-30 5-ht2b receptor antagonists

Publications (2)

Publication Number Publication Date
CA2806647A1 CA2806647A1 (en) 2012-03-08
CA2806647C true CA2806647C (en) 2018-09-18

Family

ID=43127285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2806647A Active CA2806647C (en) 2010-09-01 2011-08-30 5-ht2b receptor antagonists

Country Status (14)

Country Link
US (2) US8703958B2 (https=)
EP (1) EP2619180B1 (https=)
JP (1) JP5845263B2 (https=)
KR (1) KR101815123B1 (https=)
CN (1) CN103080089B (https=)
AU (1) AU2011298361B2 (https=)
BR (1) BR112013004503A2 (https=)
CA (1) CA2806647C (https=)
EA (1) EA020967B1 (https=)
ES (1) ES2525515T3 (https=)
MX (1) MX2013002409A (https=)
SG (1) SG188233A1 (https=)
WO (1) WO2012028614A1 (https=)
ZA (1) ZA201301561B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525515T3 (es) 2010-09-01 2014-12-23 Janssen Pharmaceutica, N.V. Antagonistas del receptor 5-HT2B
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点
US20170058349A1 (en) * 2014-03-04 2017-03-02 The Children's Hospital Of Philadelphia Methods for managing care of patients predisposed to progressive mitral valve diseases
CN110950843B (zh) * 2019-11-28 2022-12-27 广东东阳光药业有限公司 取代的苯酰胺衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8519707D0 (en) * 1985-08-06 1985-09-11 Fordonal Sa Chemical compounds
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
AU2001275326C1 (en) * 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
CN1918157B (zh) * 2004-01-07 2010-06-23 ARYx医疗有限公司 立体异构化合物及治疗胃肠道和中枢神经系统紊乱的方法
JP2009520785A (ja) 2005-12-23 2009-05-28 アストラゼネカ アクチボラグ 抗菌性のピロロピリジン、ピロロピリミジン、及びピロロアゼピン
WO2008139152A1 (en) * 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
ES2525515T3 (es) 2010-09-01 2014-12-23 Janssen Pharmaceutica, N.V. Antagonistas del receptor 5-HT2B

Also Published As

Publication number Publication date
HK1182097A1 (zh) 2013-11-22
KR101815123B1 (ko) 2018-01-04
CN103080089A (zh) 2013-05-01
EP2619180A1 (en) 2013-07-31
AU2011298361B2 (en) 2014-03-13
BR112013004503A2 (pt) 2016-06-07
US20130172386A1 (en) 2013-07-04
ES2525515T3 (es) 2014-12-23
CN103080089B (zh) 2015-09-23
ZA201301561B (en) 2014-08-27
CA2806647A1 (en) 2012-03-08
JP2013536823A (ja) 2013-09-26
EA020967B1 (ru) 2015-03-31
US9139523B2 (en) 2015-09-22
EA201390312A1 (ru) 2013-07-30
US8703958B2 (en) 2014-04-22
SG188233A1 (en) 2013-04-30
EP2619180B1 (en) 2014-10-08
MX2013002409A (es) 2013-04-03
JP5845263B2 (ja) 2016-01-20
KR20130101503A (ko) 2013-09-13
AU2011298361A1 (en) 2013-02-14
US20140187585A1 (en) 2014-07-03
WO2012028614A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
JP7190612B2 (ja) 置換ピペリジン化合物及びその用途
US20240294569A1 (en) Modulators of sortilin activity
NO329065B1 (no) Derivater av N-[fenyl(piperidin-2yl)metyl]benzamid og anvendelse av de samme i terapeutika
EP3263565A1 (en) Cyclic amine derivative and pharmaceutical use thereof
TWI872177B (zh) 對核受體具有活性之化合物
WO1997037975A1 (de) Carbonsäurederivate mit aggregationshemmender wirkung
JPH0597806A (ja) ピペリジン誘導体
CA2806647C (en) 5-ht2b receptor antagonists
JPWO2013147160A1 (ja) 環状アミン誘導体及びその医薬用途
DE60032016T2 (de) Cycloamin-ccr5-rezeptor-antagonisten
KR20130032357A (ko) 케모카인 수용체 활성의 조절제로서의 피페리디닐 화합물
WO1998017646A1 (de) 1-(4-piperidinyl)-piperidinylene, als aggregationshemmer
CN110770209B (zh) 用作p2x1及p2x3受体拮抗剂的新型5-羟基吡啶类化合物及包含其的药物组合物
WO2024044179A1 (en) Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability
HK1182097B (en) 5-ht2b receptor antagonists
KR20100097701A (ko) 비만 치료제로서의 모르폴린 유도체
CN114478360B (zh) 一种苯甲酰胺类衍生物及其制备方法和应用
JP7713953B2 (ja) 核内受容体に対して活性な化合物
WO2026006247A1 (en) 2-(piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof
KR20080041733A (ko) 티오모르폴린 화합물 및 그의 제조 방법
KR20260057182A (ko) 심장보호 지질 및 사용 방법
JP2023103981A (ja) 置換ピペリジン化合物を含有する医薬
WO2022047345A1 (en) Analogs of dextromethorphan with balanced receptor activities
AU2024332624A1 (en) Cardioprotective lipids and methods of use
CN107250129A (zh) 环状胺衍生物和其医药用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160816

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250228